Business
Perimeter Medical Imaging AI Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Perimeter Medical Imaging AI Reports Second Quarter 2024 Financial Results and Provides Corporate...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Perimeter Medical Imaging AI Reports Second Quarter 2024 Financial Results and Provides Corporate Update\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Conference Call/Webcast Today at\n \n 5 pm ET\n \n\n\n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n Aug. 14, 2024\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, today reported financial results for its second quarter ended\n \n June 30, 2024\n \n and provided a corporate update.\n \n\n\n\n\n\n\n\n\n\n\n Business Highlights\n \n\n\n\n\n The Company continues to gain positive commercial market traction with its first U.S. Food and Drug Administration (\"FDA\")-cleared product, Perimeter S-Series OCT. It has already achieved six (6) new S-Series OCT system placements year-to-date, compared to a total of three (3) for all of 2023, and Q2-2024 revenues grew 83% over Q2-2023. In addition, the Company is advancing the development of its next-generation Perimeter B-Series OCT system, which combines proprietary AI technology with OCT, toward potential commercialization.\n \n\n In\n \n May 2024\n \n , Perimeter provided an update on the ongoing pivotal clinical trial evaluating the use of its B-Series OCT system during breast-conserving surgeries (\"BCS\"). Today, based on current trends, the Company is pleased to announce that it now expects patient enrollment in the study to be completed in Q3-2024 rather than later in the 2024 fourth quarter. If successful, the trial is expected to support the Company's submission to the FDA for authorization to market Perimeter B-Series OCT in\n \n the United States\n \n in 2025.\n \n\n In\n \n June 2024\n \n , a\n \n white paper\n \n authored by\n \n Amelia A. Gunter\n \n , M.D. from the Center for Cancer and Blood Disorders,\n \n Weatherford, TX\n \n , reported results from a retrospective, quantitative assessment of reoperation rates am...